Taxol as Second-Line Treatment in Patients with Advanced Ovarian Cancer after Platinum-Based First-Line Chemotherapy

By Mayerhofer K.   Kucera E.   Zeisler H.   Speiser P.   Reinthaller A.   Sevelda P.  

Gynecologic Oncology, Vol. 64, Iss. 1, 1997-01 ,pp. : 109-113

Elsevier

Access to resources Recommend Favorite

The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer

By Kim Seung  

Medical Oncology, Vol. 27, Iss. 4, 2010-12 ,pp. : 1277-1285

Humana Press, Inc

Access to resources Recommend Favorite

Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype

By            

International Journal of Oncology, Vol. 44, Iss. 1, 2014-01 ,pp. : 17-26

Spandidos Publications

Access to resources Recommend Favorite

Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6)

By Maindrault-Goebel F.   Louvet C.   Andre T.   Carola E.   Lotz J.P.   Molitor J.L.   Garcia M.L.   Gilles-Amar V.   Izrael V.   Krulik M.   de Gramont A.  

European Journal of Cancer, Vol. 35, Iss. 9, 1999-09 ,pp. : 1338-1342

Elsevier

Access to resources Recommend Favorite

Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: A multicenter non-randomized phase II study

By Santini Daniele   Massacesi Cristian   D’Angelillo Rolando   Marcucci Fabiana   Campisi Costantino   Vincenzi Bruno   Pilone Alberta   Bianco Vincenzo   Bonsignori Maurizio   Tonini Giuseppe  

Medical Oncology, Vol. 21, Iss. 1, 2004-03 ,pp. : 59-66

Humana Press, Inc

Access to resources Recommend Favorite